Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®)

NCT06158334 · clinicaltrials.gov ↗

UNKNOWN

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Hemophilia A
Hemophilia B

Interventions

DRUG: Describe the respective haemostatic efficacy of Elocta® for haemopilia A during surgical procedures
DRUG: Describe the respective haemostatic efficacy of Alprolix® for haemopilia B during surgical procedures

Sponsor

Hospices Civils de Lyon